NCT06245213 - A Study of ANAVEX3-71 in Adults With Schizophrenia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Schizophrenia

Interventions

DRUG

ANAVEX3-71 oral capsules

ANAVEX®3-71 (formerly AF710B) is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator with agonistic effects. This novel mechanism of action offers the potential to treat all symptom domains (positive, negative, and cognitive) of schizophrenia without the side effects of standard of care antipsychotics.

DRUG

Placebo oral capsules

The placebo comparator for the study.

Trial Locations (1)

08053

CenExel Hassman Research Institute, Marlton